Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 587 participants.

Also called NCT02477969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 587 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02477969
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02477969. Randomized; triple masking; primary purpose treatment. Start 2014-02-27 (actual); primary completion 2016-06-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
PEX168(100µg)
Intervention (Drug)
PEX168(200µg)
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02477969
Content hash
ca9a86778c66a235ed2d630e6d5e53ab828d9440278225b75a0213369e048001